Adam R. Havey
Net Worth
Last updated:
What is Adam R. Havey net worth?
The estimated net worth of Mr. Adam R. Havey is at least $22,258,967 as of 1 Mar 2021. He owns shares worth $348,320 as insider, has earned $7,910,647 from insider trading and has received compensation worth at least $14,000,000 in Emergent BioSolutions Inc..
What is the salary of Adam R. Havey?
Mr. Adam R. Havey salary is $1,000,000 per year as Executive Vice President & Chief Operating Officer in Emergent BioSolutions Inc..
How old is Adam R. Havey?
Mr. Adam R. Havey is 54 years old, born in 1971.
What stocks does Adam R. Havey currently own?
As insider, Mr. Adam R. Havey owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | Executive Vice President & Chief Operating Officer | 38,190 | $9.12 | $348,320 |
What does Emergent BioSolutions Inc. do?
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Adam R. Havey insider trading
Emergent BioSolutions Inc.
Mr. Adam R. Havey has made 26 insider trades between 2011-2021, according to the Form 4 filled with the SEC.
The largest trade he's ever made was exercising 37,279 units of EBS stock on 1 Mar 2021. As of 1 Mar 2021 he still owns at least 38,190 units of EBS stock.
Emergent BioSolutions key executives
Emergent BioSolutions Inc. executives and other stock owners filed with the SEC:
- Mr. Adam R. Havey (54) Executive Vice President & Chief Operating Officer
- Mr. Atul Saran (52) Executive Vice President of Corporation Devel. & Ext. Affairs and Gen. Counsel
- Mr. Fuad El-Hibri (67) Founder & Executive Chairman
- Mr. Richard S. Lindahl (61) Executive Vice President, Chief Financial Officer & Treasurer
- Mr. Robert G. Kramer (68) Chief Executive Officer, Pres & Executive Director